NCT01226420View on ClinicalTrials.gov

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Chronic Graft-versus-host Disease
Interventions
DRUG

Alefacept

Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12

Trial Locations (3)

53226

Medical College of Wisconsin, Milwaukee

02115

Dana-Farber Cancer Institute, Boston

98109-1024

Fred Hutch Cancer Research Center, Seattle

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Astellas Pharma Inc

INDUSTRY